Capsid-Targeting Approach for HBV, HIV Fetches Novira $23M
By Jennifer Boggs
Monday, August 27, 2012
Over the past two years, the advent of protease inhibitors launched a paradigm shift that is changing the landscape of hepatitis C treatment. Now, 2009 biotech start-up Novira Therapeutics Inc. is looking to foster a similar revolution in hepatitis B, and its capsid-targeting approach got a boost last week with the closing of a $23 million Series A financing.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.